Lung-Seeking Metastases

Giulia M Stella, Stefan Kolling, Silvia Benvenuti, Chandra Bortolotto, Giulia M Stella, Stefan Kolling, Silvia Benvenuti, Chandra Bortolotto

Abstract

Metastases from different cancer types most often affect the lung parenchyma. Moreover, the lungs are among the most frequent sites of growth of metastatic masses of uncertain/unknown lineage of origin. Thus, with regards to pulmonary neoplastic parenchymal nodules, the critical issue is to determine if they are IN the lung or OF the lung. In this review, we highlight the clinical, instrumental and molecular features which characterize lung metastases, mainly focusing on recently advancing and emerging concepts regarding the metastatic niche, inflammation, angiogenesis, immune modulation and gene expression. A novel issue is related to the analysis of biomechanical forces which cooperate in the expansion of tumor masses in the lungs. We here aim to analyze the biological, genetic and pathological features of metastatic lesions to the lungs, here referred to as site of metastatic growth. This point should be a crucial part of the algorithm for a proper diagnostic and therapeutic approach in the era of personalized medicine.

Keywords: biomarkers; biomechanics; lung; metastases; metastatic niche.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Lung metastases: imaging and immunostaining. In patients with known primary tumors, the appearance of multiple bilateral pulmonary nodules is highly suggestive of metastatic dissemination and no further invasive procedures are generally required to confirm diagnosis. Chest X-Ray (CXR) has shown little sensitivity over the years, relegating it to marginal use in low-risk patients or to be abandoned entirely as a surveillance method. While lung metastases can still be detected by CXR in specific scenarios, such as incidental findings in the emergency room, computed tomography is the main imaging modality employed for detection and follow-up of lung metastases. Panel (A) CT scan presentation of lung metastases: (a) usual features of lung metastases from colorectal cancer, (b) squamous cell lung cancer of unknown primary (CUP), (c) miliary distribution of secondary lesion from ovarian cancer, (d) multiple metastatic nodules from breast cancer. Hematogenous spread to the lungs most often characterizes those tumors which arise in organs with anatomical venous drainage towards the lungs, such as head and neck, thyroid, adrenals, kidneys, testes, melanoma, and osteosarcoma. Panel (B) Computed tomography (CT) presentation of lung metastases. Computed tomography is the main imaging modality employed for detection and follow-up of lung metastases. They generally appear as round and non-calcific nodules of variable dimensions, with smooth margins and a variable degree of vascularization. However, more unusual patterns can be detected as well (such as a miliary distribution or metastatization in the form of a single lung nodule). CRC = colorectal cancer, SCC = squamous cell carcinoma, CUP = Cancer of unknown primary.
Figure 2
Figure 2
Immunohistochemical evaluation to detect the major origin of metastatic lesions: Panel (A) key screening antibody panel to detect the lineage of origin. It should be noted that melanoma is positive for vimentin but not for desmin, except for rare cases such as osteogenic melanoma which might express desmin [22] and sinovial mucosal melanoma [23]. In sarcoma desmin is not always expressed. For instance, solitary fibrous tumors and hemangioperycitoma like tumors are generally negative for desmin, as well as epitheliod sarcomas [24]. EMA = Epithelial Membrane Antigen, PLAP = Placenta Alkaline Phosphatase, Panel (B) once the diagnosis of carcinoma is reached, the cytokeratin expression may be useful to further delineate the tissue or organ of origin. The differential expression of CK 7 and CK 20 is among the most relevant discriminants of carcinomas of epithelial origin.
Figure 3
Figure 3
The journey of metastatic clones towards the lungs. The growth of metastatic masses into the lung parenchyma is orchestrated by tumor-derived signals (e.g., exosomes and genetic signatures). Once detached from the primary mass, metastatic clones invade blood (or lymphatic) vessels. Based on the interaction with adhesion molecules and based on the cross talk with chemokines and cytokines, cells reach the lung parenchyma and extravasate and colonize the pre-metastatic niche. Here, they undergo an epithelial-to-mesenchymal transition and interact with the surrounding stroma, which contributes to cell survival and growth. Moreover, smoke-induced chronic inflammation and hypoxia promote macrophage recruitment and immunotolerance.

References

    1. Rak J. Cancer: Organ-seeking vescicles. Nature. 2015;527:312–314. doi: 10.1038/nature15642.
    1. Quail D.F., Joyce J.A. Microenvironment regulation of tumor progression and metastasis. Nat. Med. 2013;19:1423–1437. doi: 10.1038/nm.3394.
    1. Turajlic S., Swanton C. Metastasis as an evolutionary process. Science. 2016;352:169–175. doi: 10.1126/science.aaf2784.
    1. Mohammed T.-L.H., Chowdhry A., Reddy G.P., Amorosa J.K., Brown K., Dyer D.S., Ginsburg M.E., Heitkamp D.E., Jeudy J., Kirsch J., et al. ACR Appropriateness Criteria® Screening for Pulmonary Metastases. J. Thorac. Imaging. 2011;26:W1–W3. doi: 10.1097/RTI.0b013e3182010bf9.
    1. Guerrera F., Renaud S., Schaeffer M., Nigra V., Solidoro P., Santelmo N., Filosso P.L., Falcoz P.-E., Ruffini E., Oliaro A., et al. Low Accuracy of Computed Tomography and Positron Emission Tomography to Detect Lung and Lymph Node Metastases of Colorectal Cancer. Ann. Thorac. Surg. 2017;104:1194–1199. doi: 10.1016/j.athoracsur.2017.05.002.
    1. Weng M.-J., Wu M.-T., Pan H.-B., Kan Y.-Y., Yang C.-F. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin. Imaging. 2004;28:408–414. doi: 10.1016/S0899-7071(03)00246-8.
    1. De Jong P.A., Leiner T., Lammers J.-W.J., Gietema H.A. Can Low-Dose Unenhanced Chest CT Be Used for Follow-Up of Lung Nodules? Am. J. Roentgenol. 2012;199:777–780. doi: 10.2214/AJR.11.7577.
    1. Willemink M.J., Noël P.B. The evolution of image reconstruction fro CT-from filtered back projection to artificial intelligence. Eur. Radiol. 2019;29:2185–2195. doi: 10.1007/s00330-018-5810-7.
    1. NCCN Clinical Practice Guidelines in Oncology, Occult Primary Version 1.2019. 31 August 2018. [(accessed on 17 July 2019)]; Available online: .
    1. Cha M.J., Park H.J., Paek M.Y., Stemmer A., Lee E.S., Bin Park S., Kim Y.S. Free-breathing ultrashort echo time lung magnetic resonance imaging using stack-of-spirals acquisition: A feasibility study in oncology patients. Magn. Reson. Imaging. 2018;51:137–143. doi: 10.1016/j.mri.2018.05.002.
    1. Ye X., Fan W., Wang H., Wang J., Wang Z., Gu S., Feng W., Zhuang Y., Liu B., Li X., et al. Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition) J. Cancer Res. Ther. 2018;14:730–744. doi: 10.4103/jcrt.JCRT_221_18.
    1. Lopez-Lopez V., Robles R., Brusadin R., López Conesa A., Torres J., Perez Flores D., Navarro J.L., Gil P.J., Parrilla P. Role of 18F-FDG PET/CT vs. CT-scan in patients with pulmonary metastases previously operated on for colorectal liver metastases. Br. J. Radiol. 2018;91:20170216. doi: 10.1259/bjr.20170216.
    1. Tan D., Zander D.S. Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update. Int. J. Clin. Exp. Pathol. 2008;1:19–31.
    1. Anderson G.G., Weiss L.M. Determining Tissue of Origin for Metastatic Cancers: Meta-analysis and Literature Review of Immunohistochemistry Performance. Appl. Immunohistochem. Mol. Morphol. 2010;18:3–8. doi: 10.1097/PAI.0b013e3181a75e6d.
    1. Reis-Filho J.S., Carrilho C., Valenti C., Leitão D., Ribeiro C.A., Ribeiro S.G., Schmitt F.C. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lungadenocarcinomas? Pathol. Res. Pract. 2000;196:835–840. doi: 10.1016/S0344-0338(00)80084-9.
    1. Moldvay J., Jackel M., Bogos K., Soltesz I., Agocs L., Kovacs G., Schaff Z. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol. Oncol. Res. 2004;10:85–88. doi: 10.1007/BF02893461.
    1. Ye J., Findeis-Hosey J.J., Yang Q., McMahon L.A., Yao J.L., Li F., Xu H. Combination of Napsin A and TTF-1 Immunohistochemistry Helps in Differentiating Primary Lung Adenocarcinoma from Metastatic Carcinoma in the Lung. Appl. Immunohistochem. Mol. Morphol. 2011;19:313–317. doi: 10.1097/PAI.0b013e318205b059.
    1. Voutsadakis I.A., Mozarowski P. Expression of TTF-1 in breast cancer independently of ER expression: A case report and pathogenic implications. Breast Dis. 2017;37:1–6. doi: 10.3233/BD-160240.
    1. Kubba L., McCluggage W.G., Liu J., Malpica A., Euscher E.D., Silva E.G., Deavers M.T. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod. Pathol. 2008;21:485–490. doi: 10.1038/modpathol.2008.4.
    1. Wieczorek T.J., Pinkus J.L., Glickman J.N., Pinkus G.S. Comparison of Thyroid Transcription Factor-1 and Hepatocyte Antigen Immunohistochemical Analysis in the Differential Diagnosis of Hepatocellular Carcinoma, Metastatic Adenocarcinoma, Renal Cell Carcinoma, and Adrenal Cortical Carcinoma. Am. J. Clin. Pathol. 2002;118:911–921. doi: 10.1309/KKDP-MND2-W794-P9EH.
    1. Minner S., Rump D., Tennstedt P., Simon R., Burandt E., Terracciano L., Moch H., Wilczak W., Bokemeyer C., Fisch M., et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer. 2012;118:1268–1275. doi: 10.1002/cncr.26436.
    1. Goto Y., De Silva M.G., Toscani A., Prabhakar B.S., Notkins A.L., Lan M.S. A novel human insulinoma-associated cDNA, IA-1, encodes a protein with “zinc-finger” DNA-binding motifs. J. Boil. Chem. 1992;267:15252–15257.
    1. To K.-F., Tong J.H., Yeung K.S., Lung R.W., Law P.P., Chau S.L., Kang W., Tong C.Y., Chow C., Chan A.W., et al. Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. J. Thorac. Oncol. 2013;8:883–891. doi: 10.1097/JTO.0b013e3182904e22.
    1. Hannouf M.B., Winquist E., Mahmud S.M., Brackstone M., Sarma S., Rodrigues G., Rogan P., Hoch J.S., Zaric G.S. Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. Pharm. J. 2017;17:286–300. doi: 10.1038/tpj.2015.94.
    1. Ross J.S., Wang K., Gay L., Otto G.A., White E., Iwanik K., Palmer G., Yelensky R., Lipson D.M., Chmielecki J., et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015;1:40–49. doi: 10.1001/jamaoncol.2014.216.
    1. Kandalaft P.L., Gown A.M. Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site. Arch. Pathol. Lab. Med. 2016;140:508–523. doi: 10.5858/arpa.2015-0173-CP.
    1. Pavlidis N., Fizazi K. Carcinoma of unknown primary (CUP) Crit. Rev. Oncol. Hematol. 2009;69:271–278. doi: 10.1016/j.critrevonc.2008.09.005.
    1. Hainsworth J.D., Fizazi K. Treatment for Patients with Unknown Primary Cancer and Favorable Prognostic Factors. Semin. Oncol. 2009;36:44–51. doi: 10.1053/j.seminoncol.2008.10.006.
    1. Murin S., Pinkerton K.E., Hubbard N.E., Erickson K. The Effect of Cigarette Smoke Exposure on Pulmonary Metastatic Disease in a Murine Model of Metastatic Breast Cancer. Chest. 2004;125:1467–1471. doi: 10.1378/chest.125.4.1467.
    1. Murin S., Inciardi J. Cigarette Smoking and the Risk of Pulmonary Metastasis from Breast Cancer. Chest. 2001;119:1635–1640. doi: 10.1378/chest.119.6.1635.
    1. Yan L., Cai Q., Xu Y. The ubiquitin-CXCR4 axis plays an important role in acute lung-infection-enhanced lung tumor metastasis. Clin. Cancer Res. 2013;19:4706–4716. doi: 10.1158/1078-0432.CCR-13-0011.
    1. Jiang M., Xu X., Bi Y., Xu J., Qin C., Han M. Systemic inflammation promotes lung metastasis via E-selectin upregulation in mouse breast cancer model. Cancer Boil. Ther. 2014;15:789–796. doi: 10.4161/cbt.28552.
    1. Stathopoulos G.T., Sherrill T.P., Han W., Sadikot R.S., Yull F.E., Blackwell T.S., Fingleton B. Host Nuclear Factor-KB Activation Potentiates Lung Cancer Metastasis. Mol. Cancer Res. 2008;6:364–371. doi: 10.1158/1541-7786.MCR-07-0309.
    1. Said N., Sanchez-Carbayo M., Smith S.C., Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Investig. 2012;122:1503–1518. doi: 10.1172/JCI61392.
    1. Wculek S.K., Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528:413–417. doi: 10.1038/nature16140.
    1. El Rayes T., Catena R., Lee S., Stawowczyk M., Joshi N., Fischbach C., Powell C.A., Dannenberg A.J., Altorki N.K., Gao D., et al. Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proc. Natl. Acad. Sci. USA. 2015;112:16000–16005. doi: 10.1073/pnas.1507294112.
    1. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., Macdonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827. doi: 10.1038/nature04186.
    1. Giancotti F.G. Mechanisms Governing Metastatic Dormancy and Reactivation. Cell. 2013;155:750–764. doi: 10.1016/j.cell.2013.10.029.
    1. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012;31:673–687. doi: 10.1007/s10555-012-9370-z.
    1. Altorki N.K., Markowitz G.J., Gao D., Port L.J., Saxena A., Stiles B., McGraw T., Mittal V. The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 2019;19:9–31. doi: 10.1038/s41568-018-0081-9.
    1. Lowy C.M., Oskarsson T. Tenascin C in metastasis: A view from the invasive front. Cell Adhes. Migr. 2015;9:112–124. doi: 10.1080/19336918.2015.1008331.
    1. Vander Griend D.J., Kocherginsky M., Hickson J.A., Stadler W.M., Lin A., Rinker-Schaeffer C.W. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 2005;65:10984–10991. doi: 10.1158/0008-5472.CAN-05-2382.
    1. Gao D., Joshi N., Choi H., Ryu S., Hahn M., Catena R., Sadik H., Argani P., Wagner P., Vahdat L.T., et al. Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Res. 2012;72:1384–1394. doi: 10.1158/0008-5472.CAN-11-2905.
    1. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial–mesenchymal transitions. Nat. Rev. Mol. Cell Boil. 2006;7:131–142. doi: 10.1038/nrm1835.
    1. Zorzetto M., Ferrari S., Saracino L., Inghilleri S., Stella G.M. MET genetic lesions in non-small-cell lung cancer: Pharmacological and clinical implications. Transl. Lung Cancer Res. 2012;1:194–207.
    1. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Boil. 2009;10:445–457. doi: 10.1038/nrm2720.
    1. Liu Y., Cao X. Organotropic metastasis: Role of tumor exosomes. Cell Res. 2015;26:149–150. doi: 10.1038/cr.2015.153.
    1. Zhang X., Yuan X., Shi H., Wu L., Qian H., Xu W. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 2015;8:83. doi: 10.1186/s13045-015-0181-x.
    1. Hoshino A., Costa-Silva B., Shen T.-L., Rodrigues G., Hashimoto A., Mark M.T., Molina H., Kohsaka S., Di Giannatale A., Ceder S., et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–335. doi: 10.1038/nature15756.
    1. Liu Y., Gu Y., Han Y., Zhang Q., Jiang Z., Zhang X., Huang B., Xu X., Zheng J., Cao X. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer Cell. 2016;30:243–256. doi: 10.1016/j.ccell.2016.06.021.
    1. Weidle U.H., Birzele F., Kollmorgen G., Rüger R. Molecular Basis of Lung Tropism of Metastasis. Cancer Genom. Proteom. 2016;13:129–139.
    1. Muramatsu M., Akakura S., Gao L., Peresie J., Balderman B., Gelman I.H. SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget. 2018;9:33515–33527. doi: 10.18632/oncotarget.26067.
    1. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelia J. A paracrine loop betwwen tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64:7022–7029. doi: 10.1158/0008-5472.CAN-04-1449.
    1. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 2009;9:239–252. doi: 10.1038/nrc2618.
    1. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., Manova-Todorova K., Leversha M., Hogg N., Seshan V.E., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150:165–178. doi: 10.1016/j.cell.2012.04.042.
    1. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011;17:867–874. doi: 10.1038/nm.2379.
    1. Malanchi I., Santamaria-Martínez A., Susanto E., Peng H., Lehr H.-A., Delaloye J.-F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481:85–89. doi: 10.1038/nature10694.
    1. Calvo A., Catena R., Noble M.S., Carbott D., Gil-Bazo I., Gonzalez-Moreno O., Huh J.I., Sharp R., Qiu T.H., Anver M.R., et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: Functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27:5373–5384. doi: 10.1038/onc.2008.155.
    1. Catena R., Bhattacharya N., El Rayes T., Wang S., Choi H., Gao D., Ryu S., Joshi N., Bielenberg D., Lee S.B., et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 2013;3:578–589. doi: 10.1158/-12-0476.
    1. Chaffer C.L., Weinberg R.A. A perspective on cell metastases. Science. 2011;331:1559–1564. doi: 10.1126/science.1203543.
    1. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., et al. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. N. Engl. J. Med. 2004;351:781–791. doi: 10.1056/NEJMoa040766.
    1. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., Shen R., Brogi E., Brivanlou A.H., Giancotti F.G. The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites. Cell. 2012;150:764–779. doi: 10.1016/j.cell.2012.06.035.
    1. Okuda R., Sekine K., Hisamatsu D., Ueno Y., Takebe T., Zheng Y.-W., Taniguchi H. Tropism of cancer stem cells to a specific distant organ. In Vivo. 2014;28:361–365.
    1. Gao W., Chen L., Ma Z., Du Z., Zhao Z., Hu Z., Li Q. Isolation and Phenotypic Characterization of Colorectal Cancer Stem Cells with Organ-Specific Metastatic Potential. Gastroenterology. 2013;145:636–646. doi: 10.1053/j.gastro.2013.05.049.
    1. Stella G.M., Luisetti M., Pozzi E., Comoglio P.M. Oncogenes in non-small-cell lung cancer: Emerging connections and novel therapeutic dynamics. Lancet Respir. Med. 2013;1:251–261. doi: 10.1016/S2213-2600(13)70009-2.
    1. Albini A., Mirisola V., Pfeffer U. Metastasis signatures: Genes regulating tumor-microenvironment interactions predict metastatic behavior. Cancer Metastasis Rev. 2008;27:75–83. doi: 10.1007/s10555-007-9111-x.
    1. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003;33:49–54. doi: 10.1038/ng1060.
    1. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massagué J. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–524. doi: 10.1038/nature03799.
    1. Gerami P., Cook R.W., Wilkinson J., Russell M.C., Dhillon N., Amaria R.N., Gonzalez R., Lyle S., Johnson C.E., Oelschlager K.M., et al. Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. Clin. Cancer Res. 2015;21:175–183. doi: 10.1158/1078-0432.CCR-13-3316.
    1. Savci-Heijink C.D., Halfwerk H., Koster J., Horlings H.M., Van De Vijver M.J. A specific gene expression signature for visceral organ metastasis in breast cancer. BMC Cancer. 2019;19:333. doi: 10.1186/s12885-019-5554-z.
    1. Vecchi M., Nuciforo P., Romagnoli S., Confalonieri S., Pellegrini C., Serio G., Quarto M., Capra M., Roviaro G.C., Avesani E.C., et al. Gene expression analysis of early and advanced gastric cancers. Oncogene. 2007;26:4284–4294. doi: 10.1038/sj.onc.1210208.
    1. Schwartz R., Schäffer A.A. The evolution of tumour phylogenetics: Principles and practice. Nat. Rev. Genet. 2017;18:213–229. doi: 10.1038/nrg.2016.170.
    1. Norton L., Massaguè J. Is cancer a disease of self-seeding? Nat. Med. 2006;12:875–878. doi: 10.1038/nm0806-875.
    1. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.-T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche. Cancer Cell. 2009;15:35–44. doi: 10.1016/j.ccr.2008.11.012.
    1. Gumireddy K., Li A., Kossenkov A.V., Cai K.Q., Liu Q., Yan J., Xu H., Showe L., Zhang L., Huang Q. ID1 Promotes Breast Cancer Metastasis by S100A9 Regulation. Mol. Cancer Res. 2014;12:1334–1343. doi: 10.1158/1541-7786.MCR-14-0049.
    1. Markowitz J., Carson W.E. Review of S100A9 biology and its role in cancer. Biochim. Biophys. Acta. 2012;1835:100–109. doi: 10.1016/j.bbcan.2012.10.003.
    1. Landemaine T., Jackson A., Bellahcène A., Rucci N., Sin S., Abad B.M., Sierra A., Boudinet A., Guinebretière J.M., Ricevuto E., et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res. 2008;68:6092–6099. doi: 10.1158/0008-5472.CAN-08-0436.
    1. Dikxhoorn D.M. MiRNAs and metastasis: Little RNAs go a long way. Cancer Res. 2010;70:6401–6406. doi: 10.1158/0008-5472.CAN-10-1346.
    1. Korpal M., Kang Y. The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Boil. 2008;5:115–119. doi: 10.4161/rna.5.3.6558.
    1. Fan Y.-C., Mei P.-J., Chen C., Miao F.-A., Zhang H., Li Z.-L. MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis. J. Neuro-Oncol. 2013;115:179–188. doi: 10.1007/s11060-013-1223-2.
    1. Cha S.T., Chen P.S., Johansson G., Chu C.Y., Wang M.Y., Jeng Y.M., Yu S.L., Chen J.S., Chang K.J., Jee S.H., et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 2010;70:2675–2685. doi: 10.1158/0008-5472.CAN-09-2448.
    1. Osaki M., Takeshita F., Sugimoto Y., Kosaka N., Yamamoto Y., Yoshioka Y., Kobayashi E., Yamada T., Kawai A., Inoue T., et al. MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression. Mol. Ther. 2011;19:1123–1130. doi: 10.1038/mt.2011.53.
    1. Sasaki R., Osaki M., Okada F. MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma. Cancers. 2019;11:553. doi: 10.3390/cancers11040553.
    1. Lam C.S., Ng L., Chow A.K., Wan T.M., Yau S., Cheng N.S., Wong S.K., Man J.H., Lo O.S., Foo D.C., et al. Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer. Oncotarget. 2017;8:26858–26870. doi: 10.18632/oncotarget.15844.
    1. Wang Z., Gao S., Li T., Ma X., Zhu H., Yan H. Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients. Medicine (Baltimore) 2018;97:e10958. doi: 10.1097/MD.0000000000010958.
    1. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: The force journey of a tumor cell. Cancer Metastasis Rev. 2009;28:113–127. doi: 10.1007/s10555-008-9173-4.
    1. Wirtz D., Konstantopoulos K., Searson P.C. The physics of cancer: The role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer. 2011;11:512–522. doi: 10.1038/nrc3080.
    1. Jain R.K., Martin J.D., Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 2014;16:321–346. doi: 10.1146/annurev-bioeng-071813-105259.
    1. Kalli M., Stylianopoulos T. Defining the Role of Solid Stress and Matrix Stiffness in Cancer Cell Proliferation and Metastasis. Front. Oncol. 2018;8:55. doi: 10.3389/fonc.2018.00055.
    1. Oudin M.J., Weaver V.M. Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harb. Symp. Quant. Boil. 2016;81:189–205. doi: 10.1101/sqb.2016.81.030817.
    1. Hoover H.C., Ketcham A.S. Metastasis of metastases. Am. J. Surg. 1975;130:405–411. doi: 10.1016/0002-9610(75)90473-0.
    1. Fidler I.J., Nicolson G.L. Fate of Recirculating B16 Melanoma Metastatic Variant Cells in Parabiotic Syngeneic Recipients: Brief Communication 2. J. Natl. Cancer Inst. 1977;58:1867–1872. doi: 10.1093/jnci/58.6.1867.
    1. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massagué J. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–1326. doi: 10.1016/j.cell.2009.11.025.
    1. Yeung T., Georges P.C., Flanagan L.A., Marg B., Ortiz M., Funaki M., Zahir N., Ming W., Weaver V., Janmey P.A. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil. Cytoskelet. 2005;60:24–34. doi: 10.1002/cm.20041.
    1. Nia H.T., Liu H., Seano G., Datta M., Jones D., Rahbari N., Incio J., Chauhan V.P., Jung K., Martin J.D., et al. Solid stress and elastic energy as measures of tumour mechanopathology. Nat. Biomed. Eng. 2017;1:0004. doi: 10.1038/s41551-016-0004.
    1. Levental I., Georges P.C., Janmey P.A. Soft biological materials and their impact on cell function. Soft Matter. 2007;3:299–306. doi: 10.1039/B610522J.
    1. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8:241–254. doi: 10.1016/j.ccr.2005.08.010.
    1. Voutouri C., Mpekris F., Papageorgis P., Odysseos A.D., Stylianopoulos T. Role of Constitutive Behavior and Tumor-Host Mechanical Interactions in the State of Stress and Growth of Solid Tumors. PLoS ONE. 2014;9:104717. doi: 10.1371/journal.pone.0104717.
    1. Tschumperlin D.J., Dai G., Maly I.V., Kikuchi T., Laiho L.H., McVittie A.K., Haley K.J., Lilly C.M., So P.T.C., Lauffenburger D.A., et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature. 2004;429:83–86. doi: 10.1038/nature02543.
    1. Roose T., Netti P.A., Munn L.L., Boucher Y., Jain R.K. Solid stress generated by spheroid growth estimated using a linear poroelasticity model. Microvasc. Res. 2003;66:204–212. doi: 10.1016/S0026-2862(03)00057-8.
    1. Xue S.-L., Yin S.-F., Li B., Feng X.-Q. Biochemomechanical modeling of vascular collapse in growing tumors. J. Mech. Phys. Solids. 2018;121:463–479. doi: 10.1016/j.jmps.2018.08.009.
    1. Harris A.L. Hypoxia—A key regulatory factor in tumour growth. Nat. Rev. Cancer. 2002;2:38–47. doi: 10.1038/nrc704.
    1. Kagan H.M., Li W. Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J. Cell. Biochem. 2003;88:660–672. doi: 10.1002/jcb.10413.
    1. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.-T., Chi J.-T.A., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226. doi: 10.1038/nature04695.
    1. Akiri G., Sabo E., Dafni H., Vadasz Z., Kartvelishvily Y., Gan N., Kessler O., Cohen T., Resnick M., Neeman M., et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 2003;63:1657–1666.
    1. Gkretsi V., Stylianopoulos T. Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis. Front. Oncol. 2018;8:145. doi: 10.3389/fonc.2018.00145.
    1. Kai F., Laklai H., Weaver V.M. Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends Cell Boil. 2016;26:486–497. doi: 10.1016/j.tcb.2016.03.007.
    1. Paszek M.J., Weaver V.M. The Tension Mounts: Mechanics Meets Morphogenesis and Malignancy. J. Mammary Gland Boil. Neoplasia. 2004;9:325–342. doi: 10.1007/s10911-004-1404-x.
    1. Janet M.T., Cheng G., Tyrrell J.A., Wilcox-Adelman S.A., Boucher Y., Jain R.K., Munn L.L. Mechanical compression drives cancer cells toward invasive phenotype. PNAS. 2012;109:911–916.
    1. Acerbi I., Cassereau L., Dean I., Shi Q., Au A., Park C., Chen Y.Y., Liphardt J., Hwang E.S., Weaver V.M. Human Breast Cancer Invasion and Aggression Correlates with ECM Stiffening and Immune Cell Infiltration. Integr. Boil. 2015;7:1120–1134. doi: 10.1039/c5ib00040h.
    1. Khaled W., Ermert H. Bioengineering in Cell and Tissue Research. Springer Science and Business Media LLC; Berlin/Heidelberg, Germany: 2008. Ultrasonic Strain Imaging and Reconstructive Elastography for Biological Tissue; pp. 103–132.
    1. Whatcott C.J., Diep C.H., Jiang P., Watanabe A., LoBello J., Sima C., Hostetter G., Shepard H.M., Von Hoff D.D., Han H. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 2015;21:3561–3568. doi: 10.1158/1078-0432.CCR-14-1051.
    1. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin signaling. Cell. 2009;139:891–906. doi: 10.1016/j.cell.2009.10.027.
    1. Croft D.R. Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and Angiogenesis. Cancer Res. 2004;64:8994–9001. doi: 10.1158/0008-5472.CAN-04-2052.
    1. Sahai E., Marshall C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nature. 2002;4:408–415. doi: 10.1038/ncb796.
    1. Wilkinson S., Paterson H.F., Marshall C.J. Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nature. 2005;7:255–261. doi: 10.1038/ncb1230.
    1. Riveline D., Zamir E., Balaban N.Q., Schwarz U.S., Ishizaki T., Narumiya S., Kam Z., Geiger B., Bershadsky A.D. Focal contacts as mechanosensors: Externally applied local mechanical force induces growth of focal contacts by an mDia1-dependent and ROCK-independent mechanism. J. Cell Biol. 2001;153:1175–1186. doi: 10.1083/jcb.153.6.1175.
    1. Tzima E., Del Pozo M.A., Shattil S.J., Chien S., Schwartz M.A. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J. 2001;20:4639–4647. doi: 10.1093/emboj/20.17.4639.
    1. Sahai E., Olson M.F., Marshall C.J. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001;20:755–766. doi: 10.1093/emboj/20.4.755.
    1. Gandalovičová A., Rosel D., Fernandes M., Veselý P., Heneberg P., Čermák V., Petruželka L., Kumar S., Sanz-Moreno V., Brábek J. Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer. 2017;3:391–406. doi: 10.1016/j.trecan.2017.04.008.
    1. Trevisan F., Tregnago A.C., Pinto C.A.L., Urvanegia A.C.M., Morbeck D.L., Bertolli E., Neto F.R.R., Neto J.P.D., De Macedo M.P. Osteogenic Melanoma with Desmin Expression. Am. J. Dermatopathol. 2017;39:528–533. doi: 10.1097/DAD.0000000000000719.
    1. Smith S.M., Schmitt A.C., Carrau R.L., Iwenofu O.H. Primary Sinonasal Mucosal Melanoma with Aberrant Diffuse and Strong Desmin Reactivity: A Potential Diagnostic Pitfall! Head Neck Pathol. 2014;9:165–171. doi: 10.1007/s12105-014-0553-5.
    1. Al-Daraji W., Husain E., Zelger B.G., Zelger B. A Practical and Comprehensive Immunohistochemical Approach to the Diagnosis of Superficial Soft Tissue Tumors. Int. J. Clin. Exp. Pathol. 2008;2:119–131.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj